1-5 of 5
Thomas Nittoli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts

Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Shu Mao, Feng Zhao, Arthur Kunz, Frank Delfino, Thomas Nittoli, Dangshe Ma, William C. Olson, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P134.
https://doi.org/10.1158/1535-7163.TARG-21-P134
Published: 01 December 2021
View article titled, Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts
Journal Articles

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade

John O. DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C. Franklin, Frank J. Delfino, Shu Mao, Feng Zhao, Jason T. Giurleo, Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W. Retter, Rabih Slim, Tara M. Young, William C. Olson, Gavin Thurston, Christopher Daly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1966–1976.
https://doi.org/10.1158/1535-7163.MCT-21-0009
Published: 01 October 2021
View article titled, A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
Open the PDF for A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade in another window
Journal Articles

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers

Marcus P. Kelly, Carlos Hickey, Sosina Makonnen, Sandra Coetzee, Sumreen Jalal, Yu Wang, Frank Delfino, Jing Shan, Terra B. Potocky, Ishita Chatterjee, Julian Andreev, Arthur Kunz, Christopher D'Souza, Jason T. Giurleo, Thomas Nittoli, Pamela A. Trail, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (7): 1299–1311.
https://doi.org/10.1158/1535-7163.MCT-16-0839
Published: 04 July 2017
View article titled, Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Open the PDF for Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, Nithya Thambi, Andres E. Perez Bay, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (4): 681–693.
https://doi.org/10.1158/1535-7163.MCT-16-0658
Published: 02 April 2017
View article titled, Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Open the PDF for Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs in another window
Includes: Supplementary data
Journal Articles

Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer

Marcus P. Kelly, Sandra Coetzee, Carlos Hickey, Sosina Makonnen, Frank Delfino, Julian Andreev, Arthur Kunz, Christopher D'Souza, Jason Giurleo, Thomas Nittoli, Pamela A. Trail, Nicholas Papadopoulos, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C126.
https://doi.org/10.1158/1535-7163.TARG-15-C126
Published: 01 December 2015
View article titled, Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer